Poster #: 1

Category: Original - Research in Progress

Title: Impact on Missing Medications by Using "Load on Demand" with Automated Dispensing Machines

Abstract:

**Purpose:** 'Load on Demand' (LOD) is the function of adding new medications to automated dispensing machines (ADM), if not already stocked, immediately after new orders are verified by a pharmacist. This study assessed the impact of LOD on medication security, availability of medications at the point of care, requests for replacement of missing medications, and the number of dispensed medications associated with the current system using 24-hour medication fills.

**Method:** This study involved a 628 bed medical center hospital with 125 ADMs and complete pharmacy services provided 24 hours a day. Implementation of LOD and data collection was conducted on adult patient units from August 1, 2017 to February 28, 2018 (7 months). Data collection included number of ADM dispenses, number of medications included in 24-hour medication fills, and number of missing medication requests from patient care units.

**Results:** Missing medication doses per week decreased from a baseline of 354 to a 3-month average of 238, or 32.8%. Twenty-four hour medication fills decreased from 379 to 81 for a 78.6% reduction. ADM dispenses increased from 72% to 90%. Reduction in doses dispensed using the 24-hr medication fills along with increased ADM dispenses resulted in improved medication security. These results were achieved with no change in ADM stock-outs.

**Conclusion:** This study shows that LOD reduces missing medications and improves medication security with no increase in staff and minimal change in workflow.

**Submitting Author:** Marilyn Garrett

**Organization:** OSF Saint Francis Medical Center

**Authors:** Marilyn E Garrett, CPhT Pharmacy Technician Supervisor OSF Saint Francis Medical Center
Title: Evaluating the effects of dexmedetomidine in addition to a standard benzodiazepine protocol in patients with alcohol withdrawal admitted to the intensive care unit

Abstract:
Purpose: Alcohol withdrawal develops upon abrupt discontinuation of alcohol exposure. Severe withdrawal may include development of agitation, seizures, and delirium tremens. Patients experiencing alcohol withdrawal symptoms are frequently monitored using the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) scale. This scale is utilized to rank alcohol withdrawal severity. The World Health Organization recommends benzodiazepines as the mainstay of alcohol withdrawal treatment(1). Occasionally, benzodiazepines do not provide adequate symptom relief and patients need additional sedation. The purpose of this study is to compare clinical outcomes between those who receive benzodiazepines alone and those who receive benzodiazepines and dexmedetomidine for alcohol withdrawal.

Methods: This single-center retrospective chart review has been approved by the local Institutional Review Board. Patients admitted to any intensive care unit (ICU) between July 1, 2015 and July 31, 2017 with a diagnosis of alcohol withdrawal syndrome or delirium tremens and initiated on the CIWA protocol will be included. Data will be collected and reviewed based on two groups: those who received benzodiazepines utilizing the CIWA-Ar protocol compared to those who received benzodiazepines utilizing the CIWA-Ar protocol with the addition of dexmedetomidine. Patients will be excluded based on age less than 18 or greater than 89 years, currently pregnant or breastfeeding, those with known allergies to the study medications, or fewer than five CIWA-Ar scores documented. The primary outcome being evaluated is the time to achieve CIWA-Ar score of less than 16 during ICU stay. Secondary outcomes include maximum change in CIWA-Ar score, time to achievement of CIWA-Ar score less than 9, hospital length of stay, ICU length of stay, average Richmond Agitation-Sedation Scale (RASS) score, incidence of delirium tremens, and total cost. Safety endpoints that will be evaluated are hypotension, bradycardia, respiratory depression, and incidence of intubation.

Results: Research in Progress

Conclusions: Research in Progress

Submitting Author: Sarah Wagner

Organization: Memorial Medical Center

Authors: Sarah Wagner, PharmD, PGY-1 Pharmacy Practice Resident, Memorial Medical Center Megan Metzke, Pharm.D., BCPS, Critical Care Clinical Pharmacist, Memorial Medical Center Billie John, Pharm.D., BCPS, Staff Pharmacist, Memorial Medical Center Don Ferrill, Pharm.D., BCPS, Manager, Pharmacy Education & Clinical Services, & PGY-1 Residency Director, Memorial Medical Center
Poster #: 3

Category: Original - Research in Progress

Title: Evaluation of acute kidney injury with mannitol versus hypertonic saline in the treatment of elevated intracranial pressure

Abstract:
Purpose: In the neurocritical care population, management of elevated intracranial pressure is crucial to reduce morbidity and mortality. A pharmacologic option is hyperosmolar therapy with mannitol or hypertonic saline, but guidelines do not have a preferred agent. Studies have shown a risk of acute kidney injury with hypertonic saline, a concern established for mannitol. History of acute kidney injury can affect prognosis and progression to chronic kidney disease. No studies have compared the safety of these agents, and due to their effects on the kidneys, this study aims to evaluate the incidence of acute kidney injury with hypertonic saline and mannitol.

Methods: This study will be submitted to the Institutional Review Board for approval. A retrospective chart review will identify patients with traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke, malignant MCA syndrome, or cerebral edema who have been treated with mannitol or 3% hypertonic saline for elevated intracranial pressure. Exclusion criteria include patients with end stage renal disease or acute kidney injury upon admission and patients 17 and younger. Any patient who received greater than 24 hours of mannitol prior to hypertonic saline or hypertonic saline prior to mannitol will be excluded. The following baseline data will be collected: age, gender, blood pressure, electrolyte levels, acute physiology and chronic health evaluation (APACHE) score, Glasgow Coma Scale, and duration of hyperosmolar therapy. Past medical history collected will include diabetes, heart failure with reduced ejection fraction, chronic kidney disease, and hypertension. Data about concurrent nephrotoxic agents and vasopressor use will also be obtained. The primary outcome will be the incidence of acute kidney injury as defined by the Kidney Disease Improving Global Outcomes guidelines. Secondary outcomes include stage of acute kidney injury, length of stay, return to baseline renal function, dialysis requirements, and incidence of hypotension. A separate multivariate logistic regression analyses for acute kidney injury will be performed to identify predictors from the following: moderate hyperchloremia, hypernatermia, days with serum sodium >145 mmol/L, metabolic acidosis, low serum bicarbonate, elevated osmolarity, elevated osmolar gap, and percent rise of the following in the first three days of therapy: sodium, chloride, serum osmolarity, and osmolar gap.

Results: Research in Progress

Conclusions: Research in Progress

Submitting Author: Rina Patel

Organization: Memorial Medical Center

Authors: Rina Patel, PharmD, PGY1 Pharmacy Practice Resident, Memorial Medical Center Katelyn Conklen, Pharm.D., BCPS, Critical Care/Trauma Clinical Pharmacist, Memorial Medical Center Don Ferrill, PharmD, BCPS, Manager, Pharmacy Education & Clinical Services & PGY-1 Residency Director, Memorial Medical Center
Abstract:
Purpose: Painful vaso-occlusive crises (VOC) are the hallmark symptom associated with adult sickle cell disease (SCD) often refractory to standard treatment. Opioids while considered the mainstay of therapy, often offer little relief, even in the setting of escalating doses. These characteristics make caring for these patients challenging and a set up for rapid onset opioid induced hyperalgesia (OIH).

The NMDA-receptor has been implicated as a driver in the development of OIH resulting in downregulation of the mu-opioid receptor, and thus refractoriness to traditional mu-opioid agonists. Ketamine a non-competitive NMDA receptor antagonist has demonstrated analgesic properties, and reported to potentially counteract these neuromodulatory changes observed in OIH. At subanesthetic doses, ketamine can help to reduce central sensitization and recouple the effects of opioids in the spinal cord to reduce opioid exposure and improve analgesic effects. Ketamine has demonstrated positive effects in cancer pain and surgical pain management as an adjuvant to opioids to help control pain, but there is little published data surrounding the use of ketamine in SCD patients. The purpose of this study is to evaluate whether the use of ketamine as part of the treatment for VOC will impact length of stay as well as contribute to the body of literature available regarding efficacy and safety of ketamine in adults with SCD with VOC pain.

Methods: This single-center, retrospective, observational study has been approved by the UCM Institutional Review Board. The UCM electronic medical record was utilized to identify the study population of adult patients 18 years of age and older admitted to the UCM adult hospital that had a diagnosis of vaso-occlusive crisis and received a ketamine infusion to help manage their pain from January 1, 2014 through June 30, 2017. Twenty-four admissions were included in the analysis from 12 unique patients.

Results: The primary endpoint comparing the length of stay when ketamine was employed compared to previous admissions where the same patient did not receive ketamine was numerically lower in the admission where ketamine was used but did not reach statistical significance (13.2 days vs 16.3 days, p=0.263). Secondary endpoints evaluating opioid doses 24 hours prior to starting ketamine versus the first 24 hours of ketamine use (1905.2 mg vs 1339.9 mg, p=0.014) as well as the opioid doses 24 hours prior to starting ketamine versus 24 hours after stopping ketamine (1905.2 mg vs 1140.4 mg, p=0.0084) were both significantly lower in patients after receiving ketamine. All opioid doses are reported in oral morphine equivalents. Time to next admission versus time since previous discharge was numerically longer after the admission where patients received ketamine, but this did not reach statistical significance (45.7 days versus 40.3 days, p=0.59).

Conclusions: This study has shown that low-dose ketamine infusions are effective at decreasing opioid usage in addition to standard pain regimens for adult patients admitted for VOC pain.

Submitting Author: Jennifer Froomkin

Organization: University of Chicago Medicine
Poster #: 5

Category: Original - Research in Progress

Title: Time Within Therapeutic Range: A Comparison of Three Tacrolimus Formulations in Renal Transplant Recipients

Abstract:
Purpose: To compare three formulations of tacrolimus (TAC) and assess differences in time within therapeutic range (TTR) and variability in levels.

Methods: Renal transplant recipients from 01/01/2013 to 10/01/2017 were retrospectively identified for analysis. Deviation from standard TAC protocol or formulation changes excluded patients. The primary outcome is percentage in TTR (%TTR) over the first 12 weeks post-transplant. Secondary outcomes include: TAC CV%, TAC levels, TAC dose, eGFR, rejection, and patient/graft survival.

Results: Research in Progress

Conclusions: Research in Progress

Submitting Author: Karen Khalil

Organization: University of Illinois Hospital & Health Sciences System

Authors: Karen A. Khalil, PharmD, PGY2 Solid Organ Transplant Pharmacy Resident; Patricia M. West-Thielke, PharmD, Director of Clinical Transplant Research; Alicia Lichvar, PharmD, MSCR, BCPS, Transplant Clinical Pharmacist; Enrico Benedetti, MD, FACS, Warren H. Cole Chair in Surgery, Professor and Head of the Department of Surgery; Shree Patel, PharmD, BCPS, Transplant Clinical Pharmacist All authors affiliated with and employed at University of Illinois Hospital & Health Sciences System.
Poster #: 6

Category: Original - Research in Progress

Title: Impact of psychological debriefing on the mental health of pharmacy residents participating in a 24-hour, in-house clinical pharmacy on-call program

Abstract:
Purpose: The clinical pharmacy on-call program at the University of Chicago Medicine is a 24-hour, in-house service provided by pharmacy residents. The on-call pharmacy resident responds to a variety of emergent clinical scenarios involving adult and pediatric patients. During these shifts the pharmacy resident may experience unfortunate or unanticipated patient outcomes which may lead to higher rates of stress, anxiety, and depression. While higher rates of depression in medical students and residents are well established, there are few studies describing mental health in pharmacy residents. This study aims to assess the impact of a 24-hour, in-house, on-call clinical pharmacy program on pharmacy resident mental health and the effects from the implementation of a formalized psychological debriefing process on stress, anxiety, and depression.

Methods: From June 2017 to June 2018, ten PGY1 pharmacy residents will be evaluated as they participate in a 24-hour, in-house, on-call clinical pharmacy program. Immediately after each shift, pharmacy residents will complete a modified Depression Anxiety Stress Scale (mDASS-21) during their first paired introductory shift, first five independent shifts, midpoint shift, and final shift. The severity of stress, anxiety, and depression will be measured as normal, mild, moderate, severe, or extremely severe. Immediately following the completion of the mDASS-21, pharmacy residents will undergo psychological debriefing with a pharmacy preceptor to discuss difficult situations and their emotional state during their shift. Compiling information from the mDASS-21 and debrief, pharmacy residents will be evaluated to assess resident mental health during the on-call shift. Statistical analysis will be performed using descriptive and univariate inferential statistics.

Results: Research in progress.

Conclusions: Research in progress.

Submitting Author: Kevin Mercer

Organization: University of Chicago Medicine

Authors: Kevin Mercer, PharmD, PGY1 Pharmacy Resident, University of Chicago Medicine; Sajni Patel, PharmD, BCPS, Cardiology Clinical Pharmacy Specialist, University of Chicago Medicine; Samantha Bastow, PharmD, BCPS, Clinical Pharmacy Manager, University of Chicago Medicine; Randall Knoebel, PharmD, BCOP, PGY1 Pharmacy Residency Program Director, University of Chicago Medicine; Hailey Soni, PharmD, BCPS, Internal Medicine Clinical Pharmacy Specialist, University of Chicago Medicine; Laura Lourenço, PharmD, BCPS, Solid Organ Transplant Clinical Pharmacy Specialist, University of Chicago Medicine; Jennifer Austin Szwak, PharmD, BCPS, Internal Medicine Clinical Pharmacy Specialist, University of Chicago Medicine
**Poster #:** 7

**Category:** Original - Research in Progress

**Title:** Impact of a PharmD consult to improve futile medication discontinuation rates in a home hospice program

**Abstract:**

Purpose: The objective of this study is to determine whether speaking with a hospice pharmacist about futile medications will improve discontinuation rates when compared with speaking with the hospice nurse. Many patients admitted to hospice have polypharmacy, many of which are deemed medically unnecessary. However, there is currently no existing data surrounding the benefit of a pharmacist in the hospice setting in terms of futile medication discontinuation rates / deprescribing. Once the patient is admitted to hospice services, these futile medications may be stopped and replaced with comfort medications. Some of these futile meds have the potential to add to the pill burden and decrease quality of life for a multitude of patients. Common futile medications include maintenance chronic obstructive pulmonary disorder (COPD) inhalers, anticoagulants, vitamins and minerals, anti-hyperlipidemia agents, and acetylcholinesterase inhibitors. The Centers for Medicare and Medicaid Services stipulates all medications must be identified as related or unrelated to the terminal prognosis, and a determination made whether hospice or a third-party payer will cover their cost, often placing unnecessary financial burden on both patients and hospice organizations. Recently a new pharmacist clinical service was launched within our hospice to address the difficulty in futile med discontinuation experienced by the nursing staff. Evaluation of the hospice pharmacist consultation service in discontinuing futile medications is the next phase of the project.

Methods: All patients referred to Hospice of Southern Illinois with an identified futile medication will be randomly assigned to usual medical care (nursing visits) or a PharmD consult where the pharmacist will discuss harms versus realistic benefits of the futile medication with the patient and/or caregiver. After IRB approval and once the study period has ended, the discontinuation rates of these futile medications between a PharmD consult and usual care will be compared. If a patient and/or caregiver requests to speak to the pharmacist, this patient will be counted as a non-discontinuation by the nurse and will not be assigned to either one of the intervention groups.

Results: Research in Progress

Conclusions: Research in Progress

**Submitting Author:** Amanda Daniels

**Organization:** Hospice of Southern Illinois

**Authors:** Amanda M Daniels, PharmD, PGY2 Pain and Palliative Care Pharmacy Resident, Hospice of Southern Illinois  Ellen Middendorf, MD, Medical Director, Hospice of Southern Illinois  Christopher M Herndon, PharmD, Professor, SIUE School of Pharmacy
Poster #: 8

Category: Encore

Title: Retrospective institutional assessment of vancomycin dosing protocol on the attainment of goal serum trough concentrations in the pediatric setting

Abstract:
Purpose: The primary objective of this study is to determine the clinical efficacy of our institution’s vancomycin collaborative practice agreement on goal serum trough concentrations in the pediatric population. Currently, patients receive starting doses of 20 milligrams/kilogram/dose every eight hours. Previous studies have shown this dose achieved goal trough concentrations (10-20 micrograms/liter) in 37% of patients. Secondary analyses will be conducted to examine vancomycin dosing variations in age groups and BMI-for-age percentiles. Currently, there is little evidence regarding effective doses in these subgroups. This study will help optimize vancomycin dosing in several patient populations.

Methods: This study will be submitted to the Institutional Review Board for approval under exempt status, and will be a retrospective cohort analysis of patient electronic medical records from a children’s hospital in central Illinois. Data will be collected from September 1, 2012 to September 1, 2017. Patients will be included if they were between the ages of 31 days and 18 years, received vancomycin per pharmacy dosing recommendations, and had at least one serum trough concentration recorded at the time of the encounter. Patients will be excluded if they were in the NICU at time of trough draw, received vancomycin for procedural prophylaxis, or received doses recommended by non-pharmacy personnel. The primary outcome will be dose at target trough concentration, which will be determined by comparing the initial dose of vancomycin to the dose that obtained goal trough levels. Secondary outcomes will include the number of dose changes to obtain target trough, time to target trough, duration of vancomycin exposure, time to de-escalation/discontinuation, frequency of dosing, frequency of trough achievement with 1st dose, serum creatinine and urine output changes, frequency of acute kidney injury under dosing protocol, and number of held doses or discontinuation due to adverse effects.

Results: Research in progress

Conclusions: Research in progress

Submitting Author: Ashley Walter

Organization: OSF Healthcare St. Francis Medical Center

Authors: Ashley Nicole Walter PGY-1 Pharmacy Resident - OSF Healthcare St. Francis Medical Center and Children's Hospital of Illinois  Doctor of Pharmacy - Butler University  Bachelor of Science - Purdue University
Poster #: 9

Category: Encore

Title: Use of a dashboard for monitoring clinical pharmacy services in a large medical center

Abstract:
Purpose: A dashboard is a management tool that provides a quick, visual picture with graphic displays or tables depicting select measures and is representative of the functioning of a business entity or division over a period of time. To qualify for use in a dashboard, items being measured should be easy to measure and obtain, reflect desired goals, account for fluctuations in populations, can clearly show current status or trends, and allow for predictions. The purpose of this report is to describe the use of a dashboard used to monitor and set goals for specific clinical services in a large medical center pharmacy department.

Methods: Fourteen measures of clinical pharmacy services in a 616-bed medical center were chosen based on desired hospital improvement targets. Four assessed elements of antimicrobial stewardship (interventions resulting from Emergency Department culture reviews, vancomycin discontinuation in patients with culture-negative neutropenia, antibiotic discontinuation on medical/surgical care unit, and reducing overall usage of piperacillin/tazobactam) and 4 measures assessed patient medication education (renal transplant patients, patients starting warfarin, any patient on anticoagulants, and any education). The remaining were measures of critical International Normalize Ratio values resulting from pharmacy dosing service, analgesia and sedation medication reviews and pro-active interventions, defects associated with admission reconciliation for renal transplant patients, elimination of inappropriate stress ulcer prophylaxis on intermediate and acute neurology units, and parenteral antihypertensive drug selection. Four dashboard items were measured hospital-wide, three focused on the critical care units, two for renal service and the remaining 5 were unit-specific. Target goals for each dashboard measure were based on desired performance and past activity. Fifteen monthly measurements for the 14 activities, adjusted for patient census, were recorded from October 2015 to December 2016. To provide a quick visual status and trend analysis, each monthly box was colored green, yellow or red representing either the specific measure is meeting or exceeding the goal, or is within about 10-20% of the goal, or exceeds 20% of the targeted goal, respectively.

Results: Over the 15 month period, seven of the 14 clinical measures showed no change, 6 met or exceeded their goals, and one showed a trend away from the goal. Two measures essentially met or exceeded theirs goals (All med education and critical INRs) and two failed to meet their goals (SUP discontinuation and antihypertensive selection) for the entire study period. Out of the 189 total monthly measurements, 85 month scores met or exceeded the desired goal (Green), 66 scores did not meet the goals by more than 20% (Red), and 38 scores were within 10% of the desired goals (Yellow). Factors that may have influenced the outcomes include overall workload volume, lower prioritization of these services, and pharmacist limitations in influencing specific outcomes. Review of goals and changes should be considered for measures showing little or no change.
Conclusions: Dashboards provide a unique method of displaying and evaluating the status of a pharmacy’s clinical services provided throughout a medical center. This 15-month report displays 14 selected measures that were used by hospital and pharmacy management, including pharmacy staff, to set desired clinical goals and to quickly assess their status over time.

**Submitting Author:** Ed Rainville

**Organization:** OSF HealthCare Saint Francis Medical Center

**Authors:** Ed, C, Rainville, BSPharm, MSPharm, FASHP, Pharmacy Supervisor, OSF HealthCare Saint Francis Medical Center, Peoria, Illinois
Title: Improving compliance with inpatient utilization of medications that have Elements to Assure Safe Use at a large academic medical center

Abstract:
Purpose: To create a standardized compliance process for medications that have Elements to Assure Safe Use (ETASU) at Northwestern Memorial Hospital (NMH).

Methods: The Food and Drug Administration (FDA) website was reviewed in September 2017 to determine which medications on the NMH formulary had ETASU requirements. Further evaluation of the ETASU requirements for the targeted NMH formulary medications was conducted to determine which had relevant inpatient requirements. Internal electronic resources were reviewed to determine what ETASU requirements were already embedded into the medication ordering and verification process. Company REMS programs were also called to verify inpatient ETASU pharmacy requirements.

Results: Review of relevant inpatient ETASU requirements resulted in identification of four formulary medications that warranted modifications to the current institutional process. Uniform actions to improve compliance with ETASU standards were proposed for order entry, pharmacist verification, electronic documentation, and staff education.

Conclusions: A standardized process was created for pharmacists to assess and document ETASU medication requirements within the electronic medical record that will generate improved compliance with ETASU regulations resulting in enhanced patient care for these selected medications.

Submitting Author: Brittany Lee

Organization: Northwestern Memorial Hospital

Authors: Brittany Lee, PharmD Northwestern Memorial Hospital PGY-1 Pharmacy Practice Resident Gerald Elliott, PharmD Northwestern Memorial Hospital PGY-1 Pharmacy Practice Resident Elizabeth Short, PharmD, BCPS, BCCCP Northwestern Memorial Hospital Practice Coordinator, Clinical Services (non-oncology)
Poster #: 11

Category: Encore

Title: Implementation of phone etiquette and triage training in pharmacy technicians at a large academic medical center

Abstract:
Purpose: To implement phone etiquette and triage techniques into pharmacy technician training to improve nurse, pharmacist, and pharmacy technician satisfaction with phone calls to the Pharmacy Department

Methods: A survey was sent out to pharmacists, pharmacy technicians, and nurses to evaluate the current satisfaction with pharmacy phone etiquette and triaging. A phone etiquette and triage program and competency checklist were created and administered to pharmacy technicians working in the central pharmacy at Northwestern Memorial Hospital. A follow-up survey was sent post phone training completion to determine if there were any changes in satisfaction or competency

Results: There were 274 responses to the pre-training survey and 60 responses to the post-training survey. Satisfaction with phone calls to the pharmacy showed improvement after phone call triage training was implemented in regards to: Time assessment Professionalism Competence Overall satisfaction The majority of responders to the first survey were nurses working day shift (67%). The proportion of responders to the second survey was approximately 1/3 each of nurses, pharmacists, and pharmacy techs.

Conclusions: Given the positive results and feedback, we plan to implement a formal phone triaging and etiquette training and competency into pharmacy technician training for both current and future employees in all pharmacy satellites. We also plan to send out a second post-training survey once all technicians have been trained and sufficient time has been passed to determine if improvement is noticed in competence and etiquette.

Submitting Author: Tyler Alverson

Organization: Northwestern Memorial Hospital

Authors: Tyler Alexsandra Alverson, PharmD, PGY1 Resident, NMH Joanna Urban, PharmD, PGY1 Resident, NMH Ana Fernandez, CPhT, Pharmacy Practice Coordinator, NMH Noelle RM Chapman, PharmD, Pharmacy Manager/PGY1 Residency Program Director, NMH